Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease

Tumori

Volumn 94, Issue 6, 2008, Pages 803-808

  Villani, Fabrizio ^a   Busia, Alessandra ^a   Villani, Massimiliano ^a   Vismara, Chiara ^a   Viviani, Simonetta ^a   Bonfante, Valeria ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cytokines; Hodgkin's disease; Lung toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROCARBAZINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; HUMAN; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PATHOGENESIS; PROTEIN BLOOD LEVEL; SPIROMETRY; TREATMENT RESPONSE;

EID: 61349124871     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400605     Document Type: Article

References (43)

1. Eghbali H, Bonichon F, David B, Rojouan J, Audebert AA, Blanc CM, Zittoun R, Hoerni B, Najman A: Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: analysis of a series of 94 patients. Radiother Oncol, 18: 127-136, 1990.
2. Cosset JM, Henry-Amar M, Meerwald JH: Long-term toxic-ity of early stage of Hodgkin's disease therapy: the EORTC experience. Ann Oncol, 2 Suppl 2: 77-82, 1991.
3. Brice P, Tredaniel J, Monsuez JJ, Marolleau JP, Ferme C, Hennequin C, Frija J, Gisselbrecht C, Boiron M: Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favourable Hodgkin's disease. Ann Oncol, 2 suppl 2: 73-76, 1991.
4. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA: Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study. J Clin Oncol, 12: 297-305, 1994.
5. Hirsch A, Vander Els N, Straus DJ, Gomez EG, Leunq D, Portlock CS, Yahalom J: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early stage Hodgkin's disease. J Clin Oncol, 14: 1297-1305, 1996.
6. Villani F, De Maria P, Bonfante V, Viviani S, Laffranchi A, Dell'Oca I, Di Russo A, Zanini M: Late pulmonary toxicity after treatment for Hodgkin's disease. Anticancer Res, 17: 4739-4742, 1997.
7. Lagrange JP: Long-term toxicity of the treatment of Hodgkin's disease. Ann Oncol, 9 Suppl 1: 133-136, 1998.
8. Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo A, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G: Long-term results of a intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am, 5: 275-282, 1999.
9. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P: ABVD plus subtotal nodal versus involved field radiotherapy in early-stage Hodkgin's disease: longterm results. J Clin Oncol, 22: 2835-2841, 2004.
10. Martinet Y, Menard O, Vaillant P, Vignaud JM, Martinet N: Cytokines in human lung fibrosis. Arch Toxicol, 18: 127-139, 1996.
11. Ward PA, Hunninghake GW: Lung inflammatory and fibrosis. Am J Respir Grit Care Med, 157: S123-S129, 1998.
12. Coker RK, Laurent GJ: Pulmonary fibrosis: cytokines in the balance. Eur Respir J, 11:1218-1221, 1998.
13. Lasky JA, Brody AR: Interstitial fibrosis and growth factors. Environ. Health Perspect, 108: 751-762, 2000.
14. Sime PJ, O'Reilly KMA: Short analytical review. Fibrosis of the lung and other tissue: new concepts in pathogenesis and treatment. Clin Immunol, 99: 308-319, 2001.
15. Stricter RM: Mechamism of pulmonary fibrosis: conference summary. Chest, 120: 77S-85S, 2001.
16. Kelly M, Kolb M, Bonniaud P, Gauldie J: Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des, 9: 39-49, 2003.
17. Antoniu KM, Alexandrakis MG, Siafakas NM, Bouros D: Cytokine network in the pathogenesis of idiopatic pulmonary fibrosis. Sarcoidosis Vase Diffuse Lung Dis, 22: 91-104, 2005.
18. Agostini C, Guerrieri C: Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc, 3: 357-363, 2006.
19. Ogilvie CM, Forster RE, Blakemore WS, Morton JW: A standardized breath holding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest, 36: 1-17, 1957.
20. th Ed. Blackwell Scientific, Boston, 1979.
21. Dinakara P, Blumenthal WS, Johnston RF, Kaufman LA, Solnick PB: The effect of anemia on pulmonary diffusing capacity with derivation of a correct equation. Am Rev Respir Dis, 102: 965-969, 1970.
22. Roughton FJW, Forster RE: Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol, 2: 290-302, 1957.
23. Els NJV, Sorhage F, Bach AM, Strauss DJ, White DA: Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease. Chest, 117: 1256-1261, 2000.
24. Piquet PE, Vesin C: Treatment by human recombinant soluble TNF receptors of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J, 7: 515-518, 1994.
25. Agostini C, Zambello R, Sancetta R, Cerutti A, Milani A, Tassinari C, Facco M, Cipriani A, Trentin L, Semenzato G: Expression of tumor necrosis factor-receptors subfamily members by lung T lymphocytes in interstitial lung disease. Am J Respir Grit Care Med, 153: 1359-1362, 1996.
26. Zhang K, Gharace-Kermani M, McGarry B, Remick D, Phan SH: TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol, 158: 954-959, 1997.
27. Sleijfer S, Vujaskovic Z, Liniburg PC, Schraffordt Koops H, Mulder NH: Induction of tumor necrosis factor-alfa as a cause of bleomycin-related toxicity. Cancer, 82:970-974,1998.
28. Lundblad LKA, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, Bates JH: Tumor necrosis factor-alfa overexpression in lung disease. A single cause behind a complex phenotype. Am J Respir Grit Care Med, 171: 1363-1370, 2005.
29. Broekelmann TJ, Limper AH, Colby TV McDonald JA: Transforming growth factor-beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci Usa, 88: 6642-6646, 1991.
30. Eickelberg O, Kohler E, Reichenberger F, Bertschin S, Woodtli T, Erne P, Perruchod AP, Roth M: Extracellular matrix deposition by primary human lung fibroblast in response to TGF-βl and TGF-β2. Am J Physiol, 276: L814-L824, 1999.
31. Selman M, Ruiz V Cabrera S, Segura L, Ramirez R, Barnios R, Pardo A: TIMP-1,-2, 3 and 4 in idiopathic pulmonary fibrosis: a prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol, 279: L562-L574, 2000.
32. Yong SJ, Adlakha A, Limper AH: Circulating transforming growth factor-betal. A potential marker of disease activity during idiopathic pulmonary fibrosis. Chest, 120: 68S-70S, 2001.
33. Ruiz V, Ordonez RM, Berumen J, Ramirez R, Uhal B, Becerril C, Pardo A, Selman M: Unbalanced collagenase/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lun Cell Mol Physiol, 285: L1026-L1036, 2003.
34. Shephard D: Transforming growth factor-beta. A central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc, 3: 413-417, 2006.
35. Marinelli WA, Polunovsky VA, Harmon KR, Bittermann PB: Role of platelet growth factor in pulmonary fibrosis. Am J Respir Crit Care Med, 5: 503-504, 1991.
36. Yi SE, Lee H, Yin S, Piquet P, Sarosi I, Kaufmann S, Tarpley J, Wang NS, Ulich TR: Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol, 149: 539-548, 1996.
37. Tada H, Ogushi F, Tani K, Nishiota Y, Miyata JY, Sato K, Asano T, Sone S: Increased binding and chemotactic capacities of PDGF-BB on fibroblasts in radiation pneumonitis. Radiat Res, 159: 805-811, 2003.
38. Zhuo Y, Zhang J, Loboy M, Lasky JA: Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol, 286: 182-188, 2004.
39. Pan LH, Ohrani H, Yamauchi K, Najura H: Co-expression of TNF-alpha and IL-1 beta in human acute pulmonary flbrotic diseases: an immunohistochemical analysis. Pathol Int, 46: 91-99, 1996.
40. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J: Transient expression of IL- 1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest, 107: 1529-1536, 2001.
41. Lappalainen U, Whitsett JA, West SE, Tichelaar JW, Bry K: Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodelling in the adult murine lung. Am. J Respir Cell Mol Biol, 32: 311-318, 2005.
42. Liu W, Ding I, Chen K, Olschowka J, Xu D, Morrow GR, Okunieff P: Interleukin 1 beta (IL-Ibeta;) signalling is a critical component of radiation-induced skin fibrosis. Radiat Res, 165: 181-191, 2006.
43. Piguet PF, Vesin C, Grau GE, Thompson RC: Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine, 5: 57-61, 1993.